Sotylize Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Sotylize Availability in 2026

As a prescriber of antiarrhythmic medications, you're likely aware that Sotylize (Sotalol hydrochloride oral solution, 5 mg/mL) has been subject to intermittent supply disruptions. This article provides an up-to-date overview of the situation, its clinical implications, and tools you can use to help your patients maintain access to therapy.

Sotylize serves a specific patient population — primarily pediatric patients, individuals with dysphagia, and patients requiring precise dose titration that the oral solution facilitates. When supply is disrupted, these patients are disproportionately affected because they cannot simply switch to the widely available tablet formulation.

Shortage Timeline and Current Status

Sotalol oral solution has appeared on the FDA drug shortage list intermittently over the past several years. Contributing factors have included:

• 2020-2022: Pandemic-related manufacturing disruptions across the pharmaceutical supply chain
• 2023-2024: Raw material sourcing challenges and quality control holds at production facilities
• 2025-2026: Continued intermittent availability; not consistently listed as a nationwide shortage, but real-world pharmacy-level stock remains unreliable

The situation is complicated by the fact that Sotalol oral solution has very few manufacturers. AltaThera Pharmaceuticals produces brand-name Sotylize, and only a small number of generic manufacturers produce Sotalol oral solution. Any disruption at a single facility has an outsized impact on supply.

Sotalol tablets (generic 80 mg, 120 mg, 160 mg, 240 mg) remain widely available and are not affected by these shortages.

Prescribing Implications

The intermittent nature of this shortage creates several prescribing challenges:

Continuity of Therapy

Sotalol should not be discontinued abruptly due to the risk of rebound tachycardia and arrhythmia exacerbation — a property shared with all beta-blockers. Patients who suddenly lose access to their supply may be at risk if they cannot fill their prescription promptly.

Initiation Requirements

Sotalol requires in-hospital initiation with continuous ECG monitoring for a minimum of 3 days (per the boxed warning). If a patient is initiated on the oral solution and later forced to switch formulations due to shortage, the transition should be carefully managed — although switching between oral solution and tablets of the same drug does not typically require re-hospitalization if the dose remains the same.

Pediatric Considerations

Pediatric patients represent the most vulnerable population during Sotylize shortages. Weight-based dosing with an oral solution offers precision that tablets cannot match, particularly for infants and young children. Compounding may be necessary (see below).

Current Availability Picture

As of early 2026:

• Brand-name Sotylize: Intermittently available; not stocked at most retail pharmacies
• Generic Sotalol oral solution: Availability varies by region and distributor
• Sotalol tablets: Widely available (generic, Betapace, Betapace AF, Sorine)
• Compounded Sotalol oral solution: Available through compounding pharmacies on a per-prescription basis

You can direct patients (and your staff) to Medfinder for Providers to check real-time pharmacy stock. This can save your team significant time compared to calling pharmacies manually.

Cost and Access Considerations

Cost may be a barrier for patients, particularly those without insurance or with high-deductible plans:

• Sotylize brand: $300-$600/month cash price
• Generic Sotalol oral solution: $150-$350/month
• Generic Sotalol tablets: $10-$40/month
• Compounded Sotalol solution: Variable; typically $50-$150 depending on pharmacy

Insurance coverage for the brand-name oral solution often requires prior authorization. Many plans apply step therapy, requiring documentation that tablets are not appropriate before covering the oral solution. Having a clear clinical rationale in the patient's chart (e.g., pediatric patient, documented dysphagia, need for precise titration) streamlines this process.

For patients needing financial help, manufacturer assistance programs and third-party resources like NeedyMeds and RxAssist are available. See our patient-facing guide: How to Save Money on Sotylize.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers real-time pharmacy inventory data. Your staff can search for Sotylize availability by zip code and direct patients to pharmacies that currently have it in stock. This is particularly useful during shortage periods.

Compounding Pharmacy Partnerships

Establishing a relationship with a local compounding pharmacy can provide a reliable backup when the manufactured product is unavailable. Compounding pharmacies can prepare Sotalol oral solution from USP-grade Sotalol hydrochloride powder. Ensure the compounding pharmacy follows USP standards.

FDA Drug Shortage Database

The FDA maintains a searchable database of current and resolved drug shortages at accessdata.fda.gov/scripts/drugshortages. This is the authoritative source for official shortage status.

Patient Education Materials

Consider sharing these resources with patients who are struggling to find Sotylize:

• How to Find Sotylize in Stock Near You
• Alternatives to Sotylize
• Sotylize Shortage Update for Patients

Alternative Antiarrhythmic Options

When Sotylize is unavailable, consider the following alternatives based on the patient's clinical profile:

• Sotalol tablets — first-line substitution for patients who can swallow tablets
• Amiodarone — broad-spectrum antiarrhythmic; appropriate for patients with structural heart disease but requires long-term toxicity monitoring
• Dofetilide (Tikosyn) — Class III alternative for AF/AFL; requires REMS-certified pharmacy and in-hospital initiation
• Dronedarone (Multaq) — for paroxysmal/persistent AF without severe HF; contraindicated in NYHA Class IV
• Flecainide — Class IC option for AF in patients without structural heart disease; often paired with a rate-controlling agent

For a patient-facing comparison, see: Alternatives to Sotylize.

Looking Ahead

The fundamental drivers of Sotylize supply instability — limited manufacturers, small market size, and fragile supply chains — are unlikely to resolve in the near term. Providers who proactively develop contingency plans (compounding partnerships, patient education, alternative protocols) will be best positioned to maintain continuity of care.

We recommend:

1. Identifying 1-2 compounding pharmacies in your area that can prepare Sotalol oral solution
2. Using Medfinder for Providers as a standard workflow tool for medication availability checks
3. Documenting clinical rationale for oral solution use in patient charts to facilitate prior authorizations
4. Educating patients to begin refill processes 7-10 days before running out

Final Thoughts

The Sotylize shortage is a manageable challenge, but it requires proactive planning. By leveraging real-time tools like Medfinder, establishing compounding relationships, and maintaining clear documentation, you can help ensure your patients continue to receive the antiarrhythmic therapy they need.

For the provider-specific guide on helping patients find this medication, see: How to Help Your Patients Find Sotylize in Stock.